Pharmacotherapy in Childhood Obesity

Kühnen, Peter; Biedermann, Heike; Wiegand, Susanna

doi:10.1159/000518432

Cited by 15 publications

(11 citation statements)

References 121 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In adults, weight-loss interventions using reduced-energy diet and exercise are associated with moderate (3–6%) weight loss at 6 months, but weight tends to be regained 25 26. For children and young people with more severe or resistant obesity, there may be a role for adjunctive pharmacotherapy, and even bariatric surgery, particularly in adolescents 23 27–29. Overall, it is difficult to achieve sustained good outcomes, particularly at the more severe end of the paediatric obesity spectrum.…”

Section: The Challenge Of Obesitymentioning

confidence: 99%

Tackling obesity while preventing obesity stigma

Darling,

Rudolf,

Rubino

et al. 2024

Arch Dis Child

View full text Add to dashboard Cite

Obesity is a significant public health problem. Prevalence is rising in children and young people, with lifelong health impacts and implications for paediatric clinical practice. Obesity stigma is increasingly acknowledged as a problem within health services. Health professionals can inadvertently contribute to this stigma, which is harmful and in itself can promote weight gain. A complex web of factors contributes to obesity, and a simplistic approach exclusively focused on personal responsibility, diet and exercise is unhelpful. A more nuanced, sensitive and informed approach is needed, with careful use of language and non-judgemental partnership working.

show abstract

Section: The Challenge Of Obesitymentioning

confidence: 99%

Tackling obesity while preventing obesity stigma

Darling,

Rudolf,

Rubino

et al. 2024

Arch Dis Child

View full text Add to dashboard Cite

show abstract

“…Even though not widely used in practice and often of modest efficacy, some treatments are now approved to treat common obesity ( 41 ). In the future, these treatments could be proposed for use in patients with syndromic or monogenic obesity, but only after careful clinical evaluation.…”

Section: Pharmacological Treatmentsmentioning

confidence: 99%

“…PWS has benefited from the most intense therapeutic research among syndromic obesity due to its severity and frequency ( 41 , 54 ). PWS leads to a hypothalamic dysfunction involved in satiety deficiency but also results in impaired oxytocin (OXT) signaling and growth hormone (GH) deficiency ( 55 ).…”

Section: Pharmacological Treatmentsmentioning

confidence: 99%

Current Treatments for Patients with Genetic Obesity

Faccioli¹,

Poitou²,

Clément³

et al. 2023

Jcrpe

View full text Add to dashboard Cite

Obesity derives from impaired central control of body weight, implying interaction between environment and an individual genetic predisposition. Genetic obesities, including monogenic and syndromic obesities, are rare and complex neuro-endocrine pathologies where the genetic contribution is predominant. Severe and early-onset obesity with eating disorders associated with frequent comorbidities make these diseases challenging. Their current estimated prevalence of 5-10% in severely obese children is probably underestimated due to the limited access to genetic diagnosis. A central alteration of hypothalamic regulation of weight implies that the leptin-melanocortin pathway is responsible for the symptoms. The management of genetic obesity has so far been only based, above all, on lifestyle intervention, especially regarding nutrition and physical activity. New therapeutic options have emerged in the last years for these patients, raising great hope to manage their complex situation and improve quality of life. Implementation of genetic diagnosis in clinical practice is thus of paramount importance to allow individualized care. This review describes the current clinical management of genetic obesity and the evidence on which it is based. Some insights will also be provided into new therapies under evaluation.

show abstract

“…Liraglutide causes dose-dependent and treatment duration-dependent thyroid C-cell tumors in rodent models, at much higher dose exposures than those used in humans. Therefore, even if the relevance for humans of such tumors has not been determined, GLP1RAs are contraindicated in patients with a family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 ( 64 ). Otherwise, gastrointestinal adverse effects are frequent in particular at start of treatment, potentially leading to discontinuation of treatment ( 65 ).…”

Section: Earlier Obesity Drug Developmentsmentioning

confidence: 99%

Treatment of hypothalamic obesity in people with hypothalamic injury: new drugs are on the horizon

Roth,

Zenno

2023

Front. Endocrinol.

View full text Add to dashboard Cite

Hypothalamic obesity (HO) is a complex and rare disorder affecting multiple regulatory pathways of energy intake and expenditure in the brain as well as the regulation of the autonomic nervous system and peripheral hormonal signaling. It can be related to monogenic obesity syndromes which often affect the central leptin-melanocortin pathways or due to injury of the hypothalamus from pituitary and hypothalamic tumors, such as craniopharyngioma, surgery, trauma, or radiation to the hypothalamus. Traditional treatments of obesity, such as lifestyle intervention and specific diets, are still a therapeutic cornerstone, but often fail to result in meaningful and sustained reduction of body mass index. This review will give an update on pharmacotherapies of HO related to hypothalamic injury. Recent obesity drug developments are promising for successful obesity intervention outcomes.

show abstract

Pharmacotherapy in Childhood Obesity

Cited by 15 publications

References 121 publications

Tackling obesity while preventing obesity stigma

Tackling obesity while preventing obesity stigma

Current Treatments for Patients with Genetic Obesity

Treatment of hypothalamic obesity in people with hypothalamic injury: new drugs are on the horizon

Contact Info

Product

Resources

About